产品名称	Adalimumab (anti-TNF-alpha), INHIBITOR of TNF-alpha inhibitor
别名	阿达莫单抗; 阿达木单抗; Adalimumab (anti-TNF-alpha); Recombinant Adalimumab Antibody; LU200134; D2E7; Anti-Human TNF-alpha, Human Antibody; Anti-TNFSF2 / TNFa Reference Antibody (adalimumab); APC1 antibody; APC1 protein antibody; Cachectin antibody; DIF antibody; D
英文别名	Sivelestat\|127373-66-4\|Ono-5046\|331731-18-1\|2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid\|ONO5046\|LY544349\|ABT-D2E7\|EI546\|Sivelestat (ONO-5046)\|UNII-FYS6T7F842\|CHEMBL76688\|DWI62G0P59\|LY-544349\|EI546;LY544349;ONO5046\|Pr
规格或纯度	ExactAb™, Validated, Carrier Free, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
特异性	TNFSF2/TNFa
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性	Cynomolgus monkey,Human,Mouse,Rhesus Macaque
偶联	Unconjugated
作用类型	抑制剂
作用机制	INHIBITOR of TNF-alpha inhibitor

AI解读

产品属性

抗体类型	Primary antibody
克隆类型	Recombinant
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	145.5 kDa
纯化方法	Protein A purified
纯度	>95% (SDS-PAGE&SEC)
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	331731-18-1

图片

ELISA: Adalimumab (anti-TNF-alpha) (A412002)

Adalimumab (anti-TNF-alpha) (A412002) - ELISA
Immobilized Recombinant Human TNF-α Protein (rp156007) at 1.0 μg/mL can bind Golimumab (anti-TNFa) (Ab175552) with the EC₅₀ of 5.78 ng/mL.

SEC: Adalimumab (anti-TNF-alpha) (A412002)

Adalimumab (anti-TNF-alpha) (A412002) - SEC
The purity of Adalimumab (anti-TNF-alpha) (A412002) is more than 95% verified by HPLC.

关联靶点（人）

TNF Tclin 肿瘤坏死因子(Tumor necrosis factor) (0 活性数据)

点击查看靶蛋白信息： TNF

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

安全和危险性（GHS）

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F0303693	分析证书	24-03-26	A412002
ZJ24F0303692	分析证书	24-03-26	A412002
ZJ24F0303691	分析证书	24-03-26	A412002

此产品的引用文献

如何在您的发表作品中引用阿拉丁的产品和网站?

1. Kempeni J. (1999) Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.. Ann Rheum Dis, 58 Suppl 1 (13): (I70-2). [PMID:10577977] [10.1021/op500134e]
2. Wollheim FA. (2002) TNF inhibition as therapy for rheumatoid arthritis.. Expert Opin Investig Drugs, 11 (7): (947-53). [PMID:12084005] [10.1021/op500134e]
3. Rau R. (2002) Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.. Ann Rheum Dis, 61 Suppl 2 (13): (ii70-3). [PMID:12379628] [10.1021/op500134e]
4. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D et al.. (2016) Adalimumab in Patients with Active Noninfectious Uveitis.. N Engl J Med, 375 (10): (932-43). [PMID:27602665] [10.1021/op500134e]
5. Kawalec P, Mikrut A, Wiśniewska N, Pilc A. (2013) Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis.. Arch Med Sci, 9 (5): (765-779). [PMID:24273556] [10.1021/op500134e]
6. Puri A, Niewiarowski A, Arai Y, Nomura H, Baird M, Dalrymple I, Warrington S, Boyce M. (2017) Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.. Br J Clin Pharmacol, 83 (7): (1405-1415). [PMID:28133772] [10.1021/op500134e]
7. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, Kumar U, Gauri LA, Jadhav P, Bartakke G et al.. (2016) A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.. Int J Rheum Dis, 19 (11): (1157-1168). [PMID:26176644] [10.1021/op500134e]
8. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. (2017) Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.. Br J Dermatol, 177 (6): (1562-1574). [PMID:28755394] [10.1021/op500134e]
9. Kronthaler U, Fritsch C, Hainzl O, Seidl A, da Silva A. (2018) Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.. Expert Opin Biol Ther, 18 (8): (921-930). [PMID:29962245] [10.1021/op500134e]

参考文献

1. Kempeni J. (1999) Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.. Ann Rheum Dis, 58 Suppl 1 (13): (I70-2). [PMID:10577977] [10.1021/op500134e]
2. Wollheim FA. (2002) TNF inhibition as therapy for rheumatoid arthritis.. Expert Opin Investig Drugs, 11 (7): (947-53). [PMID:12084005] [10.1021/op500134e]
3. Rau R. (2002) Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.. Ann Rheum Dis, 61 Suppl 2 (13): (ii70-3). [PMID:12379628] [10.1021/op500134e]
4. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D et al.. (2016) Adalimumab in Patients with Active Noninfectious Uveitis.. N Engl J Med, 375 (10): (932-43). [PMID:27602665] [10.1021/op500134e]
5. Kawalec P, Mikrut A, Wiśniewska N, Pilc A. (2013) Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis.. Arch Med Sci, 9 (5): (765-779). [PMID:24273556] [10.1021/op500134e]
6. Puri A, Niewiarowski A, Arai Y, Nomura H, Baird M, Dalrymple I, Warrington S, Boyce M. (2017) Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.. Br J Clin Pharmacol, 83 (7): (1405-1415). [PMID:28133772] [10.1021/op500134e]
7. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, Kumar U, Gauri LA, Jadhav P, Bartakke G et al.. (2016) A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.. Int J Rheum Dis, 19 (11): (1157-1168). [PMID:26176644] [10.1021/op500134e]
8. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. (2017) Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.. Br J Dermatol, 177 (6): (1562-1574). [PMID:28755394] [10.1021/op500134e]
9. Kronthaler U, Fritsch C, Hainzl O, Seidl A, da Silva A. (2018) Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.. Expert Opin Biol Ther, 18 (8): (921-930). [PMID:29962245] [10.1021/op500134e]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Adalimumab (anti-TNF-alpha), INHIBITOR of TNF-alpha inhibitor

库存信息

库存信息

库存信息

库存信息

基本信息

AI解读

产品属性

图片

关联靶点（人）

安全和危险性（GHS）

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关文档

此产品的引用文献

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器